- Two CEOs met at Seegene headquarters to discuss and concurred with Seegene's vision
- Seegene's swift responses to the COVID-19 pandemic and digital solutions through AI implementation were presented
According to the company,
Highlighting Seegene's rapid response to the Covid-19 pandemic,
Seegene has facilitated the rapid and effective isolation of individuals infected with COVID-19 by delivering approximately 350 million diagnostic tests to over 100 countries.
"We greatly value the visit of UKHSA, a world-leading health security agency, to Seegene," said
SG OneSystem™ business, or Seegene's technology sharing initiative, is a global strategy aimed at eradicating diseases. It involves sharing the company's syndromic quantitative PCR technology and Seegene's Digitalized Development System (SGDDS) with leading companies worldwide. The initiative enables scientists across the globe to contribute directly to the development of locally tailored diagnostic reagents for various diseases affecting humans, animals, and plants.
To effectively advance this endeavor, Seegene has forged strategic collaborations with industry and academic leaders including Microsoft (NASDAQ:MSFT) and Springer Nature, underscoring its commitment to advancing global health solutions through the enhancement of its technology sharing initiative.
About Seegene
Seegene has 23 years of dedicated R&D, manufacturing and business experience around syndromic quantitative PCR technologies, which was highlighted during the COVID-19 pandemic when it provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene's unique syndromic PCR technologies is the ability to simultaneously test 14 pathogens that cause similar symptoms in a single tube and provide quantitative information on the infectivity profile to correlate with the severity of illness.